Almonertinib is a third-generation, oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor primarily indicated for the treatment of patients with EGFR mutation-positive non-small cell lung… Read more






Almonertinib is a third-generation, oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor primarily indicated for the treatment of patients with EGFR mutation-positive non-small cell lung cancer. This category contains high-quality reference standards of the parent drug, alongside its related compounds, including synthetic impurities, N-nitroso derivatives, and stable isotope-labelled analogues such as Almonertinib-d6. Pharmaceutical laboratories utilize these materials for rigorous impurity profiling, accurate quantification during method validation, and ongoing quality control of drug substances and drug products. By employing these precise reference materials, analytical chemists can reliably identify and monitor degradation products and manufacturing by-products, ensuring compliance with regulatory standards throughout the drug development lifecycle.